Basementboy Posted - 6 minutes from now

$RPTX Time is running out on Repare’s hope of finding a partner for RP-3467. Repare will start a registrational trial for MYTHIC in 2025. Without a partner for either of these two trials, where will Repare get the financing to stay solvent? As a contingency, CEO Segal is considering a Convertible Debt strategy see attached - https://ir.reparerx.com/static-files/3866d993-79bc-4380-a4cc-19e04a267891#page29 Note, Interest on $100.0M loan @ 8.5% over six years would equate to total Interest payments of $30.0M A stream of revenue would need to accompany a Convertible Debt strategy because the revenue stream covers the monthly Interest accrued. So what revenue stream is Repare expecting? 1. Will the FDA allow Repare to commercialize the MYTHIC drugs to satisfy ‘Additional Treatment Solutions’ in gynecological cancers? 2. Will the NCI step forward with grant money while they advance the development of Camonsertib? 3. Is expecting BMS to place one of their identified targets into the clinic? Is this just leverage used against Suitors to get their Price?

Basementboy Posted - 11 hours ago

$RPTX With the Q3 Institutional reporting deadline being Nov 15th, here is a summary of the Tute Activity for the Quarter; Deep Track <904.3K> Square Point <37.5K> Two Sigma <23.6K> Goldman <20.2K> Square Point <68.0K> Morgan Stanley <99.0K> Corton <75.1K> Susquehanna <44.6K> PDT <30.0K> Millennial <146.2K> ARK Investment <120.6K> GSA <59.1K> Sumitomo <28.0K> Cubist 21.2K Acadian 29.6K Aquilo 32.4K Marshall 36.5K Affinity 173.3K BlackRock 143.3K Net shares <1,220.0K> https://fintel.io/so/us/rptx

Basementboy Posted - 1 day ago

$RPTX Shorts covered 330.0K shares in early afternoon and then another 330.0K shares right after the bell. I suppose the tutes that were shorting this ticker were ’tipped-off’ about pending news Be nimble and Be ready!

Cpaken Posted - 4 days ago

$RPTX made it my biggest holding today. This has nothing to do vaccines, today’s panic sell-off is unjustified

Cpaken Posted - 5 days ago

$RPTX added more, this has huge potential

Cpaken Posted - 6 days ago

$RPTX looks like they were hunting for the stop-losses

Cpaken Posted - 6 days ago

$RPTX added more, all the stars are aligned for this to rocket

Basementboy Posted - 1 week ago

$RPTX Repare registered their S-3 ‘Shelf Offering’ on August 6th for $350.0M, and today they reported an ATM Prospectus for $100.0M with TD Cowen acting as their agent. The market has the share price pegged at $3.60/shr which means the company will increase O/S share count by ~25.7M shares. Will Repare sell the Prospectus before or after the MYTHIC results which are due out in December? Who will buy all these shares? https://ir.reparerx.com/static-files/3866d993-79bc-4380-a4cc-19e04a267891

Cpaken Posted - 1 week ago

$RPTX easily going back to 8

Cpaken Posted - 1 week ago

$RPTX Trump is good for biotechs

Cpaken Posted - 1 week ago

$RPTX back in with doubled position

Almora34 Posted - 2 weeks ago

$RPTX Out with a little profit for now. May rebuy at 3.5

Basementboy Posted - 10/31/24

$RPTX MYTHIC trial data due out late Q4, so probably around December 14th …. a lot of pain between now and then

Stocks4thought Posted - 10/29/24

$RPTX $WVE maybe $GSK waves to this one too- https://www.gsk.com/en-gb/behind-the-science-magazine/synthetic-lethality-accelerating-precision-cancer-treatments/

Cpaken Posted - 10/29/24

$RPTX all out for now,good luck guys

briefingcom Posted - 10/23/24

$RPTX: Repare Therapeutics presents updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib and camonsertib https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241023061255RPTX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

RonFarms Posted - 10/23/24

$RPTX ^

Stocks4thought Posted - 1 month ago

$RPTX Old but informative https://www.gsk.com/en-gb/behind-the-science-magazine/synthetic-lethality-accelerating-precision-cancer-treatments/

Stocks4thought Posted - 1 month ago

$APRE $rptx Sim Simpsons- look alike Rad3-

Stocks4thought Posted - 1 month ago

$BWAY $15 next ot $PRQR $VKTX $SLNO $RPTX others

Stocks4thought Posted - 1 month ago

$PRQR Belgium rocks------ot $RPTX $PRME $VYGR

Mnof Posted - 1 month ago

$RPTX IMO - Large Pharma will partner Repare on their pol theta inhibition program. There is reason to believe that Lynparza (and therefore other PARPi) and RP-3467 can act in synergy (slide 15) ir.reparerx.com/static-file... and overcome PARPi resistance. If this can be substantiated clinically then you have the grounds for patent extension for the next 20 yrs for your PARPi program. As an example, key Lynparza patents in various countries are currently expiring or set to expire soon (see below), it may be a catalyst for Azn/Merck to get on board or other pharmas with PARPi programs (Pfizer or AbbVie). Interesting time, watch this space.

Basementboy Posted - 1 month ago

$RPTX Did you guys catch that reference to exploring RP-3467 in ADC’s in today’s PR “. … the potential for RP-3467 to improve efficacy and limit toxicity in combination with radioligand therapy and chemotherapy-bearing antibody drug conjugates (ADCs), and we look forward to exploring those areas” Could that be ABBVie they are looking to partner with?

Stocks4thought Posted - 1 month ago

$RPTX Sexy ot $SLNO $Rani We are one step closer to potentially improving the lives of patients with the first patient dosed with RP-3467, our potential best-in-class Polθ ATPase inhibitor by demonstrating complete and durable tumor regressions in combination with olaparib with no additive toxicities.

Mikrus36 Posted - 1 month ago

$RPTX https://x.com/RepareRx/status/1845792897028809204

themacromindset Posted - 1 month ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor $RPTX'

Basementboy Posted - 1 month ago

$RPTX Is the attached abstract a biomarker from the MAGNETIC trial with Gemcitabine? https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-23-4130/747395/Low-Molecular-Weight-Cyclin-E-Confers-a?redirectedFrom=fulltext Many of the contributing authors are from Texas MD Anderson Cancer Centre MAGNETIC is Active, not recruiting https://clinicaltrials.gov/study/NCT05147272

Cpaken Posted - 1 month ago

$RPTX back in

Basementboy Posted - 1 month ago

$RPTX Repare most likely announces 1st patient dosed in POLAR trial today

Basementboy Posted - 1 month ago

$RPTX Just a couple of items to share after listening to Repare’s H.C. Wainwright presentation Sept 11th; 1. BMS is ‘ … pushing ahead’ with the targets Repare identified 2. Following the resent Lunre results with FOLFIRI, ‘ … exploring opportunities, and weighing partner options’ 3. Repare’s CMO, Maria Koehler, ‘ … believes the market for Camonsertib mono for NSCLC will be double ALK https://alk.lungevity.org/alk/about-alk-positive-lung-cancer# If Repare was able to capture 75% of a ‘ … double ALK’ that would give Repare a MC of $4.674B if commercialization occurred by 2027 Camonsertib NSCLC ATMm NPV $4,674,982,857 Disc Finance Rate 30% Investment Cost ($150.0M) Yr 1 - ‘27 $2.186B Yr 2 - ‘28 $2.413B Yr 3 - ‘29 $2.664B Yr 4 - ‘30 $2.941B Yr 5 - ‘31 $3.247B Assumption 1. The global NSCLC market was a $16.1B market in 2021 and has a CAGR of 10.104%. If Camonsertib is FDA approved in 2027 and captures 7.5% of the entire NSCLC global market